BioVie Inc. (BIVI) stock
BIVINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as BIVIW
$0.80−0.11 (-12.07%)
Close on Nov 20, 2026Market cap $6.03MP/E –Yield –
BioVie shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
BioVie's shares outstanding was 8M at Jun 30, 2026. For fiscal 2026 it was 7M, up 390.5% from the year before. Over ten years it grew 26.4% a year on average. The highest annual figure on record is 25M in fiscal 2022.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | 7M | +390.5% |
| FY2025 | Jun 30, 2025 | 1M | +227.0% |
| FY2024 | Jun 30, 2024 | 0M | -86.1% |
| FY2023 | Jun 30, 2023 | 3M | -86.8% |
| FY2022 | Jun 30, 2022 | 25M | +98.8% |
| FY2021 | Jun 30, 2021 | 12M | +151.6% |
| FY2020 | Jun 30, 2020 | 5M | +94.1% |
| FY2019 | Jun 30, 2019 | 3M | +231.5% |
| FY2018 | Jun 30, 2018 | 1M | +7.1% |
| FY2017 | Jun 30, 2017 | 1M | +2.5% |
| FY2016 | Jun 30, 2016 | 1M | -0.0% |
| FY2015 | Jun 30, 2015 | 1M | +0.1% |
| FY2014 | Jun 30, 2014 | 1M | +111.2% |
| FY2013 | Jun 30, 2013 | 0M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | 8M | +326.4% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | 8M | +307.6% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | 8M | +404.0% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | 5M | +715.0% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | 2M | -58.5% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | 2M | -51.5% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | 2M | -57.2% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | 1M | -98.2% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | 4M | -85.6% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | 4M | -86.0% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | 4M | -85.3% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | 35M | +41.4% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | 31M | +24.9% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | 27M | +14.7% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | 25M | +58.1% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | 25M | +79.5% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | 25M | +79.4% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | 24M | +297.2% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | 16M | +204.0% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | 14M | +167.7% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | 14M | +168.5% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | 6M | +44.5% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | 5M | +95.0% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | 5M | +108.2% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | 5M | +561.3% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | 4M | +432.9% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | 3M | +251.4% |
| Q1 FY2019CQ3 2018 | Dec 31, 2018 | 2M | +234.6% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | 1M | +6.8% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | 1M | +6.0% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | 1M | +8.4% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | 1M | +7.0% |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | 1M | +5.3% |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | 1M | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | 1M | – |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | 1M | – |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | 1M | – |
See a number that looks wrong?